Staff turmoil continues at Focus Surgery, the Milpitas, CA, developerof high-frequency ultrasound ablation products. The firm announcedlate last month that CFO John Kehoe has stepped down. His dutieswill be assumed temporarily by vice president of
Staff turmoil continues at Focus Surgery, the Milpitas, CA, developerof high-frequency ultrasound ablation products. The firm announcedlate last month that CFO John Kehoe has stepped down. His dutieswill be assumed temporarily by vice president of planning PaulSullivan.
Kehoe's departure came several weeks after Focus cut its workforce by 40% (SCAN 9/27/95). Focus has posted a string of losingquarters as it moves to commercialize its Sonablate 200 productfor treatment of benign prostatic hyperplasia. The company saidlast month that it "continues to examine all financing alternatives,"but declined to be more specific about what those alternativesmight be.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.